Fortive Management
Management criteria checks 2/4
Fortive's CEO is Olumide Soroye, appointed in Jun 2025, has a tenure of less than a year. total yearly compensation is $14.41M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.085% of the company’s shares, worth $15.01M. The average tenure of the management team and the board of directors is 1.3 years and 5.2 years respectively.
Key information
Olumide Soroye
Chief executive officer
US$14.4m
Total compensation
| CEO salary percentage | 6.47% |
| CEO tenure | less than a year |
| CEO ownership | 0.08% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Narrative Update • May 20
FTV: Buybacks And Sequential Execution Will Support Future Earnings Quality
Fortive's analyst price target has been raised by several firms in recent research, collectively edging higher by single digits in dollar terms. Analysts point to solid sequential growth and recent company execution to support slightly higher revenue growth and P/E expectations, even as profit margin assumptions are trimmed and the discount rate is nudged up.Narrative Update • May 02
FTV: Sterilization Demand And Buybacks Will Support Future Earnings Quality
Fortive's analyst fair value estimate has been nudged up by $1 to $73 after analysts weighed a mix of recent price target increases and trims alongside recalibrated assumptions for growth, margins and future P/E levels. Analyst Commentary Recent Street research on Fortive shows a mix of target price trims and increases, with bullish analysts generally leaning toward higher fair value assumptions even as some recalibrate their models.
Narrative Update • Apr 16
FTV: Future P E Compression Will Challenge Buyback Support At Current Levels
Fortive's analyst price targets have seen a mixed reset, with one firm trimming its view by $7 while several others lifted their targets by $4 to $9, as analysts factor in modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Fortive shows a mix of optimism and caution, with several firms lifting their price targets and one trimming its view by $7.Seeking Alpha • Apr 14
Fortive: Starting To Improve Its Performance
Summary Fortive has executed well post-Ralliant spin-off, delivering solid earnings and modest organic growth, supporting a fair valuation. Fortive's 2025 sales rose 2% to $4.16B, with 4Q organic growth exceeding 3%; adjusted EPS reached $2.71, up $0.30 YoY. Guidance targets 2026 adjusted EPS of $2.90–$3.00, underpinned by 2–3% organic growth, margin gains, and continued buybacks. At 19–20x forward earnings and leverage in the mid-2s, Fortive offers reasonable value, though upside is capped without stronger growth catalysts. Read the full article on Seeking AlphaNarrative Update • Apr 02
FTV: Fair Value View Balances Buybacks Against Execution And P E Compression Risks
Analysts have nudged their fair value estimate for Fortive higher to $52.50 from $51.10, reflecting updated views on revenue growth, margins, and future P/E assumptions following a mix of recent price target hikes and one downgrade across the Street. Analyst Commentary Recent Street research on Fortive shows a mixed but generally cautious tone, with a cluster of price target increases alongside at least one downgrade and a later price target cut.Narrative Update • Mar 19
FTV: Fair Value Case Weighs Buybacks Against Execution And Multiple Compression Risks
Fortive's analyst price target has been adjusted slightly lower to $51.10. Analysts point to updated fair value estimates, refined discount rate assumptions, and refreshed views on revenue growth, margins, and future P/E multiples following a series of recent price target revisions across major firms.Narrative Update • Mar 05
FTV: North American Sterilization Demand Will Support Future Earnings Quality Upside
Analysts have lifted their price targets on Fortive, supporting a move in our fair value estimate from $66.00 to $72.00. They cited updated expectations for revenue growth, profitability and a lower forward P/E multiple.
Narrative Update • Feb 19
FTV: Recent Rating Shift And Buybacks Will Shape Future Return Profile
Our updated Fortive narrative reflects a higher implied price target of about $62, as analysts factor in steadier revenue growth assumptions, slightly stronger profit margins, a modestly lower discount rate, and a similar forward P/E, consistent with a series of recent price target increases across the Street. Analyst Commentary Recent Street research shows a cluster of higher Fortive price targets, alongside at least one downgrade.Narrative Update • Feb 04
FTV: JPMorgan Downgrade And Buybacks Will Shape A Measured Return Profile
Analysts have trimmed their price target on Fortive to US$58.13, citing a slightly lower discount rate, modestly softer revenue expectations and a higher assumed profit margin supported by a reduced future P/E multiple. Analyst Commentary Recent commentary around the new US$58.13 price target reflects a mixed view on Fortive, with the latest JPMorgan downgrade underlining both execution opportunities and areas of concern for valuation and growth.Narrative Update • Jan 21
FTV: Balanced Outlook As Healthcare Demand And Buybacks Shape Future Returns
Narrative Update The analyst price target for Fortive has shifted from approximately $56.13 to $58.13, as analysts cite recent model updates and sequential improvements in North American demand for sterilization and biomedical equipment, along with higher AHS adjusted EBITDA driven by gross profit growth and lower costs. Analyst Commentary Recent research on Fortive reflects a mix of optimism on execution and caution around upside potential, which is showing up in both price target changes and rating shifts.Narrative Update • Jan 06
FTV: Fair Value View Balances Higher Demand With Margin Execution Risks
Analysts have increased their fair value estimate for Fortive from US$50.00 to US$52.00, citing refreshed models after the Q3 report and Street research that points to improved North American demand for sterilization and biomedical equipment, stronger AHS adjusted EBITDA margins, and updated price targets clustered around US$55 to US$58. Analyst Commentary Recent Street research on Fortive points to updated price targets clustered in the US$55 to US$58 range, with analysts revising their models following the Q3 report.Analysis Article • Dec 27
Estimating The Fair Value Of Fortive Corporation (NYSE:FTV)
Key Insights The projected fair value for Fortive is US$53.12 based on 2 Stage Free Cash Flow to Equity Current share...Narrative Update • Dec 15
FTV: North American Sterilization Demand Will Support Earnings Quality And Upside Potential
Analysts have modestly raised their blended price target on Fortive to about $58 per share from roughly $55, citing improved North American demand for sterilization and biomedical equipment, stronger margins in Advanced Healthcare Solutions, and updated post earnings financial models that still reflect slightly softer long term growth and profitability assumptions. Analyst Commentary Bullish analysts are pointing to a constructive risk reward profile for Fortive, highlighting that incremental execution gains and healthier end market trends can support the recent step up in valuation.Narrative Update • Oct 20
Recurring Software Trends Will Secure Resilience Amid Tariff Uncertainty
Analysts have lowered their fair value estimate for Fortive to $56.13 from $57.25. They cite a tougher outlook and more challenging revenue growth projections for the remainder of the year.Narrative Update • Sep 18
Recurring Software Trends Will Secure Resilience Amid Tariff Uncertainty
Analysts have lowered Fortive's price target to $57.25 due to skepticism over the company's ability to meet guidance amid slowing growth in its strongest segment, caution around macro headwinds post-Ralliant spinoff, and minimal near-term revenue growth. Analyst Commentary Persistent skepticism regarding Fortive's ability to achieve its full-year guidance following a cautious update and lack of supportive industry data.Narrative Update • Sep 03
Recurring Software Trends Will Secure Resilience Amid Tariff Uncertainty
Analysts have lowered Fortive’s target price to $60.50, citing uncertainty about achieving updated guidance following the Ralliant spin-off, ongoing topline and margin pressures, and diminished visibility post-restructuring. Analyst Commentary Bullish analysts highlight Fortive's high earnings visibility and strong recurring revenue profile (~50%+), expecting portfolio reviews and strategic focus on workflow management software and healthcare to support margin resilience.Analysis Article • May 30
A Look At The Intrinsic Value Of Fortive Corporation (NYSE:FTV)
Key Insights Fortive's estimated fair value is US$88.69 based on 2 Stage Free Cash Flow to Equity Fortive's US$71.07...Seeking Alpha • Mar 10
Fortive Seeing Signs Of Improvement, But Valuation Doesn't Make It An Easy Call
Summary Fortive's fourth-quarter results (and full 2024 results) showed fairly ordinary performance, with revenue and margins missing targets, and the business model didn't meaningfully outperform peers through the cycle. 2025 should be a better year, and I'd expect Fortive's businesses to recover ahead of more manufacturing and machinery-focused peers. The upcoming split of Precision Technologies into Ralliant may reduce complexity but is unlikely to significantly add or destroy value, but I can see potential strategic bidders for Tektronix. Despite cautious optimism for 2025, FTV's valuation doesn't justify a premium, given its inability to outgrow inflation and deliver superior full-cycle performance. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Fortive Corporation: Undervaluation And Stability Give It An Edge (Rating Upgrade)
Summary Fortive Corporation's product innovations and increased bookings, particularly in cloud-based solutions, support a recovery by 2025 despite macro uncertainties delaying short-term growth. The company’s strong cash flow, robust liquidity, and undervaluation compared to peers justify an upgrade to a "Buy" rating. Fortive's solid balance sheet, aggressive share repurchase policy, and stable cash flow position it well for superior medium-term returns. Read the full article on Seeking AlphaSeeking Alpha • Sep 22
Fortive: A Softer Performance Triggers A Separation
Summary Fortive is a solid conglomerate operating in three segments, focusing on intelligent operating solutions, precision technologies and healthcare solutions. After a softer performance of the precision technologies business this year, the company has announced plans to separate the business. The company trades at reasonable valuations and leverage, with a potential for higher valuation post-separation, expected to complete by Q4 2025. I recommend initiating positions in the $70s or high $60s, as the business separation may drive significant shareholder value. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Apr 03 2026 | n/a | n/a | US$557m |
| Dec 31 2025 | US$14m | US$932k | US$533m |
| Sep 26 2025 | n/a | n/a | US$885m |
| Jun 27 2025 | n/a | n/a | US$879m |
| Mar 28 2025 | n/a | n/a | US$388m |
| Dec 31 2024 | US$8m | US$764k | US$483m |
| Sep 27 2024 | n/a | n/a | US$555m |
| Jun 28 2024 | n/a | n/a | US$661m |
| Mar 29 2024 | n/a | n/a | US$900m |
| Dec 31 2023 | US$8m | US$750k | US$408m |
| Sep 29 2023 | n/a | n/a | US$828m |
| Jun 30 2023 | n/a | n/a | US$800m |
| Mar 31 2023 | n/a | n/a | US$764m |
| Dec 31 2022 | US$7m | US$750k | US$755m |
| Sep 30 2022 | n/a | n/a | US$696m |
| Jul 01 2022 | n/a | n/a | US$659m |
| Apr 01 2022 | n/a | n/a | US$650m |
| Dec 31 2021 | US$14m | US$274k | US$580m |
Compensation vs Market: Olumide's total compensation ($USD14.41M) is about average for companies of similar size in the US market ($USD14.79M).
Compensation vs Earnings: Olumide's compensation has increased by more than 20% in the past year.
CEO
Olumide Soroye (52 yo)
less than a year
Tenure
US$14,405,012
Compensation
Mr. Olumide O. Soroye is President, CEO & Director of Fortive Corporation from June 28, 2025. Mr. Soroye serves as Indpendent Director of Verisk Analytics, Inc. since August 19 2022. He was President and C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$14.41m | 0.085% $ 15.0m | |
| Senior VP & CFO | 1.2yrs | US$21.41m | 0.045% $ 8.1m | |
| Senior VP & Chief Legal Officer | 10yrs | US$5.09m | 0.029% $ 5.1m | |
| Chief Accounting Officer | 6.6yrs | no data | 0.023% $ 4.0m | |
| Senior VP & Chief Technology and Business System Officer | 1.2yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief People Officer | less than a year | no data | no data | |
| President of Fluke & Group President of Connected Reliability Group (CRG) | no data | no data | no data | |
| President of Gordian and Group President of Facilities & Asset Lifecycle (FAL) Group | no data | no data | no data | |
| President of ASP & Group President of Infection Prevention Group (IPG) | 1.3yrs | no data | no data | |
| President of Provation & Group President of Healthcare Productivity and Quality (HPQ) Group | 1.3yrs | no data | no data | |
| Group President of Environmental | 1.3yrs | no data | no data |
1.3yrs
Average Tenure
52yo
Average Age
Experienced Management: FTV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$14.41m | 0.085% $ 15.0m | |
| Independent Director | 9.8yrs | US$346.73k | 0.0017% $ 296.3k | |
| Independent Director | 5.2yrs | US$322.42k | 0.013% $ 2.2m | |
| Independent Director | 7.3yrs | US$347.42k | 0.0014% $ 248.4k | |
| Independent Director | 3.3yrs | US$272.42k | 0.0015% $ 260.8k | |
| Independent Director | 4.3yrs | US$321.20k | 0.0028% $ 502.1k | |
| Independent Director | 5.4yrs | US$335.85k | 0.0014% $ 248.4k | |
| Independent Chair of the Board | 5.8yrs | US$544.87k | 0.0014% $ 248.4k | |
| Independent Director | 1.3yrs | US$332.42k | no data |
5.2yrs
Average Tenure
60yo
Average Age
Experienced Board: FTV's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 08:52 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/04/03 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortive Corporation is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |